Bedford Pharmacy Recalls P-P-P Injection Due to Sterility Concerns
Bedford Pharmacy is recalling 4 vials of P-P-P (COBAL) 30-1-20/mL Injection due to a lack of assurance of sterility. The product was distributed in New Hampshire and Massachusetts.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II, and the rubric specifies that FDA Class II recalls with potential for hospitalization or significant injury are rated as Severe (4).
Plain-English summary
Bedford Pharmacy is recalling 4 vials of P-P-P (COBAL) 30-1-20/mL Injection. The recall was initiated because of a lack of assurance of sterility for the product. The specific lot number is 08132015@9, with an expiration date of 09/27/2015.
The affected product was distributed in New Hampshire and Massachusetts. The recall is classified as FDA Class II by the U.S. Food and Drug Administration.
Consumers who have this product should stop using it and contact their healthcare provider or the recalling firm for further instructions.
The recalled product
- Product
- P-P-P (COBAL) 30-1-20/mL, Injection, Bedford Pharmacy, 209 Route 101, Bedford, NH 03110, (603) 472-3919
- Manufacturer
- Bedford Pharmacy
- Category
- Drug — Injection
- Hazard
- Affected units
- 4
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: 08132015@9
- Exp 09/27/2015
Distribution
Part of a larger recall action
This product is one of 13 recalled by Bedford Pharmacy under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 13 products in this recall →Related recalls
Same manufacturer · Bedford Pharmacy
See all →- HighBedford Pharmacy Recalls P-P-P Injection Due to Sterility Concerns
FDA (Drugs) · 2015-10-21
- SevereBedford Pharmacy Recalls P-P-P Injection Due to Sterility Concerns
FDA (Drugs) · 2015-10-21
- SevereBedford Pharmacy Recalls P-P (COBAL) Injection Due to Sterility Concerns
FDA (Drugs) · 2015-10-21
- SevereBedford Pharmacy Recalls P-P (COBAL) Injection Due to Sterility Concerns
FDA (Drugs) · 2015-10-21
- SevereBedford Pharmacy Recalls P-P (COBAL) Injection Due to Sterility Concerns
FDA (Drugs) · 2015-10-21
Same hazard · sterility
See all →- SevereAurolab Trust Recalls FOCUS PI Eye Drops Due to Sterility Concerns
FDA (Drugs) · 2026-10-07
- SevereSterling Recalls Carboxymethylcellulose Sodium Eye Drops Due to Sterility Concerns
FDA (Drugs) · 2026-09-30
- SevereSterling Pharmaceutical Recalls Lubricating Tears Due to Sterility Concerns
FDA (Drugs) · 2026-09-30
- SevereWalgreens Lubricant Eye Drops Recalled for Sterility Assurance Concerns
FDA (Drugs) · 2026-09-30
- SevereSodium Chloride Ophthalmic Solution Recalled for Sterility Assurance Issues
FDA (Drugs) · 2026-09-30
Similar recalls
- SevereB&B Pharmacy Recalls PGE 30mcg/ml Injection Due to Sterility Concerns
FDA (Drugs) · 2015-11-18
- SeverePGE 20mcg/ml Injection Recalled Due to Sterility Assurance Concerns
FDA (Drugs) · 2015-11-18
- SevereDowning Labs Recalls Methylcobalamin Injection Due to Sterility Concerns
FDA (Drugs) · 2015-11-25
- SeverePGE 25mcg/ml Injection Recalled Due to Sterility Assurance Concerns
FDA (Drugs) · 2015-11-18
- SeverePharmakon Recalls Propofol Injection Due to Sterility Concerns
FDA (Drugs) · 2016-07-20
- SevereB&B Pharmacy Recalls PAPA/PGE1/PHENTO Injection Due to Sterility Concerns
FDA (Drugs) · 2015-11-18